AGENT FOR PREVENTING OR TREATING FATTY LIVER

PURPOSE: To obtain a medicine containing conagenin as an active ingredient, useful for preventing and treating the fatty liver, and high in safety. CONSTITUTION: The agent for preventing or treating the fatty liver contains conagenin of the formula or its salt as an active ingredient. The conagenin acts as a low molecular immunoregulation factor, suppresses the activation of macrophages, is low toxic, stimulates the release of neutral fats in blood, and suppresses hepatic hypetrophy which is the side effect of a medicine. The conagenin is compounded with a conventional liquid or solid carrier, and the obtained medicinal composition is prepared into an oral agent, an injection agent or a rectal suppository by a conventional method. The conagenin is administered parenterally at a dose of 0.1-500mg/day, or orally at a dose of 0.5-2.5g/day. The chemical name of the conagenin is (2S)-N-[(2R,3S,4R)-2,4- dihydroxy-3-methyl-pentanoyl]-2-methylserine.